Andre P. Fay, Karim Fizazi, Nobuaki Matsubara, Arun Azad, Fred Saad, Ugo De Giorgi, Jae Young Joung, Peter C.C. Fong, Robert Jones Jones, Stefanie Zschaebitz, Jan Oldenburg, Neal D. Shore, Curtis J Dunshee, Joan Carles, Paul Cislo, Cynthia Healy, Melissa Kirker, Neeraj Agarwal. "Final patient-reported outcomes (PROs) in men with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations receiving initial treatment with talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA in the TALAPRO-2 study.." Journal of Clinical Oncology (2025). https://doi.org/10.1200/jco.2025.43.16_suppl.11121